Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Abstract

In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom,

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

“…Despite these limitations, this study has many strengths: the availability of splenectomy status in a very large study population undergoing allo‐HCT in the last 20 years, homogeneous conditioning platforms, detailed information on spleen size in a vast majority of non‐splenectomised patients and robust follow up 55 …”

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus

“…The annual activity survey of the EBMT reflects current activity and trends in the field of transplant technology. It is valuable for the dissemination of the most recent information on indications, donor and stem cell usage, and benchmarking of data completeness, and survival outcomes [30], which can ultimately be beneficial in health care planning.…”

“…The survey using a standardized structure captures the numbers of HCT from highly committed participating teams, divided by indication, donor type, and stem cell source. In the last years with the dramatic increase of cellular therapies, the survey also includes information on cellular therapies with hematopoietic cells for uses other than to replace the hematopoietic system [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. The analysis of the survey data since 1990 shows a continued and constant increase in the annual numbers of HCT and transplant rates for both allogeneic and autologous HCT.…”

Setting up a Hematopoietic Stem Cell Transplantation Unit

“…A unique stepped process is under development for transplant programs in low- and middle-income countries (LMICs), where full accreditation might not be feasible due to resources and cultural issues. Fee for accreditation as of February 2018 is €14,600 for EBMT members and €29,200 for non-EBMT members (Snowden et al 2020 ; LeMaistre et al 2019 ).…”